郑州大学第一附属医院，又名郑州大学第一临床学院，简称郑大一附院，原名河南医科大学第一附属医院，是附属于郑州大学的一家三级甲等医院，也是河南省最大的三级甲等医院。

During the past decade, The First Affiliated Hospital of Zhengzhou University conducted 284 clinical trials. In the 10-year time frame, 284 clinical trials started and 14 clinical trials were completed, i.e. on average, 4.9% percent of trials that started reached the finish line to date. In the past 5 years, 178 clinical trials started and 12 clinical trials were completed. i.e. 6.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The First Affiliated Hospital of Zhengzhou University" #1 sponsor was "The First Affiliated Hospital of Zhengzhou University" with 25 trials, followed by "BeiGene" with 9 trials sponsored, "Jiangsu HengRui Medicine Co., Ltd." with 9 trials sponsored, "Hoffmann-La Roche" with 8 trials sponsored and "Chia Tai Tianqing Pharmaceutical Group Co., Ltd." with 8 trials sponsored. Other sponsors include 253 different institutions and companies that sponsored additional 179 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The First Affiliated Hospital of Zhengzhou University" #1 collaborator was "The First Affiliated Hospital of Zhengzhou University" with 44 trials as a collaborator, "First Affiliated Hospital of Xinjiang Medical University" with 10 trials as a collaborator, "Chinese PLA General Hospital" with 6 trials as a collaborator, "Nanyang Central Hospital" with 6 trials as a collaborator and "The Second Hospital of Hebei Medical University" with 6 trials as a collaborator. Other collaborators include 602 different institutions and companies that were collaborators in the rest 419 trials.

According to Clinical.Site data, the most researched conditions in "The First Affiliated Hospital of Zhengzhou University" are "Gastric Cancer" (9 trials), "Advanced Solid Tumor" (8 trials), "Coronary Artery Disease" (7 trials), "Esophageal Squamous Cell Carcinoma" (7 trials) and "Breast Cancer" (5 trials). Many other conditions were trialed in "The First Affiliated Hospital of Zhengzhou University" in a lesser frequency.

Most popular intervention types in "The First Affiliated Hospital of Zhengzhou University" are "Drug" (208 trials), "Device" (52 trials), "Biological" (22 trials), "Other" (17 trials) and "Procedure" (15 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (47 trials), "Tislelizumab" (8 trials), "Cisplatin" (7 trials), "Paclitaxel" (7 trials) and "Capecitabine" (6 trials). Other intervention names were less common.

The vast majority of trials in "The First Affiliated Hospital of Zhengzhou University" are 301 trials for "All" genders, 11 trials for "Female" genders and 3 trials for "Male" genders.

Currently, there are 152 active trials in "The First Affiliated Hospital of Zhengzhou University". 18 are not yet recruiting, 105 are recruiting, 26 are Active, not recruiting, and 3 are Enrolling by invitation. In total, there were 75 completed trials in The First Affiliated Hospital of Zhengzhou University, 1 suspended trials, and 12 terminated clinical trials to date.

Out of the total trials that were conducted in The First Affiliated Hospital of Zhengzhou University, 43 "Phase 1" clinical trials were conducted, 97 "Phase 2" clinical trials and 84 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 20 trials, and there were also 59 trials that are defined as “Not Applicable".

The First Affiliated Hospital of Zhengzhou University has several departments that took part in Clinical trials: "Oncology Department of The First Affiliated Hospital of Zhengzhou University" - 19 trials, "Henan Infectious Diseases Hospital" - 3 trials, "Children's Hospital Affiliated to Zhengzhou University/Henan Children's Hospital" - 2 trials